Sarepta's Duchenne Gene Therapy Linked to Second Patient Death

Sarepta Therapeutics has halted shipments of its Duchenne muscular dystrophy gene therapy, Elevidys, after the death of a second non-ambulatory patient due to acute liver failure, prompting the company to work with experts and the FDA to develop a safer immunosuppressive regimen.